// App-Quantinova.ai

TPS8627 : MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN + DEX).

Researchers

Presenter

  • David Samuel DiCapua Siegel

Principal Investigators

  • Richy Agajanian

  • Rakesh Gaur

  • Yasir M. Nagarwala

  • Michael Sturniolo

  • Rosanna J. Ricafort

  • Gail Larkins

  • Shankar Srinivasan

  • Rajesh Chopra

  • Anjan Thakurta

  • Flavio Kruter

  • Kasra Karamlou

  • Hakan Kaya

Medical Centers

  • The Oncology Institute of Hope and Innovation, Downey, CA

  • St Lukes Cancer Institute, Kansas City, MOCelgene Corporation, Summit, NJBay Area Cancer Research Group, Pleasant Hill, CA

  • Carroll Regional Cancer Center, Westminister, MD

  • John Theurer Cancer Center, Hackensack, NJ

  • Cancer Care Northwest, Spokane, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Creatinine

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Aspirin

  • Albyl-E

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01946477

Sponsors

  • Celgene

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved